ProCE Banner Activity

Expert Answers to Clinician Questions Regarding Optimal Management of Patients With Myelodysplastic Syndrome

Clinical Thought
Experts answer questions on the optimal use of oral decitabine and FLT3 inhibitors and the current management of patients with low-risk and high-risk MDS.

Released: January 11, 2021

Expiration: January 10, 2022

Share

Faculty

Guillermo Garcia-Manero

Guillermo Garcia-Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Rami S. Komrokji

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Jamile Shammo

Jamile Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Director, MDS/MPN/Aplastic Anemia Program 
Rush University Medical Center
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Taiho Oncology Inc

Faculty Disclosure

Primary Author

Guillermo Garcia-Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Guillermo Garcia-Manero, MD, has disclosed that he has received funds for research support from Bristol-Myers Squibb and consulting fees from Bristol-Myers Squibb and Taiho.

Rami S. Komrokji, MD

Professor of Oncologic Sciences
Department of Oncologic Sciences
University of Florida
Senior Member/Clinical Director
Malignant Hematology
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida

Rami S. Komrokji, MD, has disclosed that he has received consulting fees from AbbVie, Acceleron, Bristol-Myers Squibb, Geron, Incyte, and Jazz and fees for non-CME/CE services from Agios, Bristol-Myers Squibb, and Jazz.

Jamile Shammo, MD, FASCP, FACP

Professor of Medicine and Pathology
Division of Hematology, Oncology, and Stem Cell Transplant
Director, MDS/MPN/Aplastic Anemia Program 
Rush University Medical Center
Chicago, Illinois

Jamile Shammo, MD, FASCP, FACP, has disclosed that she has received funds for research support from AbbVie, Alexion, Bristol-Myers Squibb, CTI, Incyte, Kartos, Novartis, Onconova, and Telios; consulting fees from Alexion, Apellis, Bristol-Myers Squibb, Incyte, and Novartis; has received fees for non-CME/CE services from Alexion, Bristol-Myers Squibb, Incyte, and Sanofi; and has stock/ownership interest from AbbVie, Baxter, and Takeda.